$2.00 EPS Expected for Humana Inc. (HUM); Dicerna Pharmaceuticals, Inc. (DRNA) Covered By 3 Bullish Analysts Last Week

January 14, 2018 - By Vivian Currie

Among 5 analysts covering Dicerna Pharmaceuticals (NASDAQ:DRNA), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Dicerna Pharmaceuticals had 17 analyst reports since August 7, 2015 according to SRatingsIntel. Chardan Capital Markets maintained it with “Neutral” rating and $3.50 target in Monday, August 15 report. Stifel Nicolaus maintained it with “Buy” rating and $13 target in Thursday, June 30 report. The company was maintained on Wednesday, November 11 by Stifel Nicolaus. The firm has “Buy” rating by H.C. Wainwright given on Monday, December 12. The firm has “Outperform” rating given on Tuesday, September 8 by Cowen & Co. The rating was maintained by H.C. Wainwright on Friday, August 11 with “Buy”. The company was maintained on Tuesday, July 18 by Cowen & Co. On Wednesday, August 16 the stock rating was maintained by Cowen & Co with “Buy”. The firm has “Mkt Perform” rating given on Tuesday, January 31 by Leerink Swann. As per Friday, August 11, the company rating was maintained by Chardan Capital Markets. See Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) latest ratings:

02/11/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $10.0 Maintain
16/08/2017 Broker: Cowen & Co Rating: Buy Maintain
11/08/2017 Broker: Chardan Capital Markets Rating: Hold Maintain
11/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $6.0000 Maintain
18/07/2017 Broker: Cowen & Co Rating: Buy Maintain

Analysts expect Humana Inc. (NYSE:HUM) to report $2.00 EPS on February, 14.They anticipate $0.09 EPS change or 4.31% from last quarter’s $2.09 EPS. HUM’s profit would be $279.15M giving it 33.50 P/E if the $2.00 EPS is correct. After having $3.39 EPS previously, Humana Inc.’s analysts see -41.00% EPS growth. The stock increased 1.06% or $2.81 during the last trading session, reaching $268.02. About 1.57M shares traded or 28.21% up from the average. Humana Inc. (NYSE:HUM) has risen 35.38% since January 14, 2017 and is uptrending. It has outperformed by 18.68% the S&P500.

Among 23 analysts covering Humana (NYSE:HUM), 14 have Buy rating, 0 Sell and 9 Hold. Therefore 61% are positive. Humana had 67 analyst reports since July 30, 2015 according to SRatingsIntel. As per Friday, July 22, the company rating was maintained by FBR Capital. The stock of Humana Inc. (NYSE:HUM) has “Buy” rating given on Friday, January 12 by Jefferies. The stock of Humana Inc. (NYSE:HUM) earned “Buy” rating by Bank of America on Friday, July 14. The firm has “Outperform” rating given on Friday, November 11 by Credit Suisse. Jefferies maintained Humana Inc. (NYSE:HUM) rating on Tuesday, June 6. Jefferies has “Hold” rating and $23000 target. The firm has “Outperform” rating by Oppenheimer given on Thursday, March 30. The rating was upgraded by JP Morgan on Thursday, November 10 to “Overweight”. Jefferies maintained the stock with “Hold” rating in Tuesday, September 5 report. The rating was maintained by Jefferies with “Buy” on Thursday, August 4. The rating was maintained by Cowen & Co with “Outperform” on Wednesday, April 26.

Humana Inc., together with its subsidiaries, operates as a health and well-being firm in the United States. The company has market cap of $37.41 billion. The firm operates through three divisions: Retail, Group, and Healthcare Services. It has a 21.26 P/E ratio. The Retail segment offers Medicare benefits, as well as commercial fully-insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products directly to individuals or through group accounts.

Investors sentiment increased to 1.21 in Q3 2017. Its up 0.01, from 1.2 in 2017Q2. It is positive, as 44 investors sold Humana Inc. shares while 184 reduced holdings. 76 funds opened positions while 201 raised stakes. 131.39 million shares or 2.57% less from 134.86 million shares in 2017Q2 were reported. Sit Inv Assocs owns 0.07% invested in Humana Inc. (NYSE:HUM) for 12,020 shares. Cibc Asset reported 16,748 shares stake. Old Mutual Investors (Uk) Limited accumulated 441,325 shares or 1.12% of the stock. 20,062 are held by Mason Street. Colony Grp Inc Ltd Liability Com has invested 0.02% in Humana Inc. (NYSE:HUM). Caprock Grp invested in 0.06% or 1,169 shares. First Quadrant Lp Ca holds 0.12% or 24,801 shares. Parametric Associates accumulated 451,212 shares. Vanguard Group owns 10.04M shares. Jacobs Levy Equity Mgmt stated it has 0.58% of its portfolio in Humana Inc. (NYSE:HUM). Credit Agricole S A holds 0.07% or 79,442 shares. Bbr owns 96,050 shares. Balasa Dinverno Foltz Ltd Liability Com accumulated 1,211 shares or 0.05% of the stock. Mirae Asset Investments Ltd invested in 0.01% or 3,267 shares. Manufacturers Life Insur The invested in 0.05% or 156,959 shares.

Since August 10, 2017, it had 0 insider purchases, and 7 sales for $16.22 million activity. Huval Timothy S. sold $2.01 million worth of stock or 7,803 shares. BROUSSARD BRUCE D sold $3.02M worth of Humana Inc. (NYSE:HUM) on Friday, August 11. Fleming William Kevin sold $770,760 worth of stock or 3,071 shares. Christopher M Todoroff sold 22,935 shares worth $5.79M. BILNEY JODY L sold $1.75 million worth of stock. Bierbower Elizabeth D sold 9,786 shares worth $2.53M.

Since December 18, 2017, it had 1 buy, and 0 selling transactions for $2.00 million activity. The insider Bain Capital Life Sciences Investors – LLC bought $2.00 million.

The stock decreased 0.12% or $0.01 during the last trading session, reaching $8.42. About 132,779 shares traded. Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has declined 5.22% since January 14, 2017 and is downtrending. It has underperformed by 21.92% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: